Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
2.14
Dollar change
-0.12
Percentage change
-5.31
%
IndexRUT P/E- EPS (ttm)-1.16 Insider Own23.07% Shs Outstand186.96M Perf Week-9.70%
Market Cap430.95M Forward P/E- EPS next Y-0.44 Insider Trans2.95% Shs Float154.92M Perf Month-27.95%
Income-118.00M PEG- EPS next Q-0.16 Inst Own65.08% Short Float8.68% Perf Quarter-11.20%
Sales14.16M P/S30.43 EPS this Y59.11% Inst Trans-1.64% Short Ratio4.99 Perf Half Y49.65%
Book/sh0.29 P/B7.43 EPS next Y-12.62% ROA-92.70% Short Interest13.45M Perf Year204.58%
Cash/sh0.62 P/C3.46 EPS next 5Y- ROE-606.69% 52W Range0.62 - 4.32 Perf YTD20.90%
Dividend Est.- P/FCF- EPS past 5Y-137.69% ROI-104.56% 52W High-50.46% Beta0.39
Dividend TTM- Quick Ratio3.36 Sales past 5Y129.39% Gross Margin87.81% 52W Low245.16% ATR (14)0.24
Dividend Ex-Date- Current Ratio3.36 EPS Y/Y TTM57.75% Oper. Margin-559.09% RSI (14)37.74 Volatility7.64% 9.71%
Employees52 Debt/Eq1.13 Sales Y/Y TTM96.39% Profit Margin-833.60% Recom1.09 Target Price6.59
Option/ShortYes / Yes LT Debt/Eq1.10 EPS Q/Q62.67% Payout- Rel Volume0.57 Prev Close2.26
Sales Surprise18.36% EPS Surprise6.80% Sales Q/Q-27.52% EarningsMay 14 AMC Avg Volume2.70M Price2.14
SMA20-8.80% SMA50-26.17% SMA200-8.08% Trades Volume1,549,485 Change-5.31%
Date Action Analyst Rating Change Price Target Change
Jun-27-24Initiated BMO Capital Markets Outperform $5
Apr-09-24Initiated Piper Sandler Overweight $9
Feb-01-23Downgrade Jefferies Buy → Hold $14 → $1.50
Jan-27-23Downgrade Morgan Stanley Overweight → Equal-Weight $23 → $3
Nov-09-22Downgrade Goldman Buy → Neutral $16 → $3
Mar-09-22Initiated Robert W. Baird Outperform $26
Mar-01-22Initiated Wells Fargo Overweight $25
Feb-18-22Initiated SMBC Nikko Outperform $25
Dec-16-21Initiated Guggenheim Buy $28
Jul-16-21Initiated Needham Buy $45
Jul-05-24 08:00AM
Jun-26-24 09:14AM
08:36AM
07:41AM
Jun-25-24 06:34PM
07:30AM Loading…
Jun-18-24 07:30AM
07:02AM
Jun-13-24 06:00AM
Jun-12-24 07:00AM
Jun-07-24 08:00AM
Jun-03-24 04:31PM
04:17PM
May-15-24 03:11AM
May-14-24 08:57PM
05:15PM
05:03PM Loading…
05:03PM
04:01PM
May-07-24 04:05PM
May-03-24 04:05PM
May-02-24 10:01AM
08:00AM
Apr-29-24 01:37PM
Apr-15-24 05:30AM
Apr-05-24 08:00AM
Mar-20-24 11:19AM
08:01AM
Mar-19-24 08:53PM
04:01PM
Mar-14-24 04:26PM
Mar-01-24 05:08PM
08:00AM Loading…
Feb-29-24 08:00AM
Feb-15-24 04:01PM
Feb-02-24 08:00AM
Jan-31-24 02:23PM
Jan-22-24 08:00AM
Jan-15-24 09:30AM
Jan-10-24 08:00AM
Jan-05-24 08:00AM
Dec-19-23 07:30AM
Nov-29-23 08:00AM
Nov-15-23 02:00PM
12:52PM
Nov-14-23 06:35PM
04:08PM
Nov-07-23 08:00AM
Oct-24-23 08:00AM
Oct-10-23 08:00AM
Sep-26-23 08:00AM
Sep-19-23 04:01PM
Sep-05-23 09:55AM
Sep-04-23 03:04PM
Aug-24-23 08:00AM
Aug-15-23 01:54AM
Aug-14-23 07:02AM
07:00AM
Jul-31-23 08:00AM
Jul-18-23 07:08AM
Jun-28-23 08:00AM
Jun-15-23 08:00AM
Jun-05-23 08:00AM
May-19-23 12:54PM
08:00AM
May-16-23 11:41AM
May-12-23 10:15AM
May-11-23 04:01PM
May-04-23 08:00AM
Apr-27-23 04:52PM
Apr-15-23 08:24AM
Mar-30-23 06:08AM
Mar-28-23 04:01PM
Mar-15-23 04:01PM
Feb-14-23 05:32PM
Feb-08-23 05:42AM
Jan-31-23 04:01PM
Jan-24-23 02:32PM
Dec-19-22 02:05PM
Dec-16-22 06:19PM
Dec-01-22 09:55AM
Nov-29-22 04:01PM
Nov-08-22 07:00AM
Nov-03-22 08:26PM
Nov-02-22 07:00AM
Oct-26-22 07:54PM
11:05AM
06:13AM
Oct-25-22 04:01PM
03:55PM
09:31AM
08:15AM
Oct-24-22 07:35PM
07:30PM
Oct-06-22 07:00AM
Aug-29-22 07:35AM
Aug-12-22 08:30AM
Aug-11-22 07:00AM
Aug-09-22 05:22PM
Aug-01-22 07:00AM
Jul-19-22 08:39AM
Jul-06-22 07:00AM
Jun-13-22 08:39AM
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Manning Paul B10% OwnerJun 27 '24Buy2.251,333,3332,999,9991,333,333Jul 01 08:00 AM
Manning Paul B10% OwnerNov 17 '23Buy1.63100,000163,00016,566,667Nov 20 07:35 AM
Alam KamranChief Financial OfficerAug 24 '23Sale2.3333,00076,890258,042Aug 25 04:30 PM
Manning Paul B10% OwnerAug 16 '23Buy0.9016,466,66714,820,00016,466,667Aug 16 08:57 PM
Nolan Sean P.Chief Executive OfficerAug 16 '23Buy0.90444,444400,0001,535,545Aug 16 08:52 PM
Stalfort John A IIIDirectorAug 16 '23Buy0.90388,889350,000884,290Aug 16 08:53 PM
Stalfort John A IIIDirectorAug 16 '23Buy0.90388,889350,000999,381Aug 16 08:53 PM
Donenberg Phillip B.DirectorAug 16 '23Buy0.90111,111100,000114,111Aug 16 08:51 PM